secwatch.observer — SEC 8-K summary
======================================

Issuer:     COMPASS Pathways plc (CMPS)
CIK:        0001816590
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001628280-25-008414
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Pathways reports FY2024 net loss of $155.1M; Phase 3 data on track for Q2 2025
--------------------------------------------------------------------------------

- Net loss for FY2024 was $155.1M ($2.30 loss per share) vs $118.5M ($2.32 loss per share) in FY2023.
- Cash and cash equivalents $165.1M at Dec 31, 2024; additional $140.4M net raised in Q1 2025.
- Phase 3 COMP005 top-line 6-week data for TRD on track for Q2 2025; COMP006 26-week data expected H2 2026.
- R&D expenses rose to $119.0M from $87.5M, driven by phase 3 trials and strategic reorganization costs.
- Steve Levine, M.D., appointed Chief Patient Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816590/000162828025008414/0001628280-25-008414-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816590/000162828025008414/cmps-20250227.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-008414

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer